Results 11 to 20 of about 43,902 (289)

Long-term use of denosumab and its association with skeletal-related events and osteonecrosis of the jaw

Scientific Reports, 2023
Denosumab, an inhibitor of receptor activator of nuclear factor kappa-B ligand, reduces skeletal-related events (SREs) and is approved for solid tumors with bone metastases.
Pei-An Fu, Chin-Yao Shen, Shuen‑Ru Yang, Chun-Hui Lee, Hui-Wen Chen, Edward Chia-Cheng Lai, Wei-Pang Chung   +6 more
doaj   +2 more sources

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

JCI Insight, 2023
Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear.
Qiang Fu, Nancy C. Bustamante-Gomez, Humberto Reyes-Pardo, Igor Gubrij, Diana Escalona-Vargas, Jeff D. Thostenson, Michela Palmieri, Joseph J. Goellner, Intawat Nookaew, C. Lowry Barnes, Jeffrey B. Stambough, Elena Ambrogini, Charles A. O’Brien   +12 more
doaj   +2 more sources

Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension [PDF]

Osteoporosis International, 2023
Summary In postmenopausal women with osteoporosis, up to 10 years of denosumab treatment significantly and continuously improved bone microarchitecture assessed by tissue thickness–adjusted trabecular bone score, independently of bone mineral density ...
Didier Hans, Michele McDermott, Shuang Huang, Min Kim, Enisa Shevroja, Michael R. McClung   +5 more
openalex   +2 more sources

Denosumab and incidence of type 2 diabetes among adults with osteoporosis: population based cohort study

British medical journal, 2023
Objective To estimate the effect of denosumab compared with oral bisphosphonates on reducing the risk of type 2 diabetes in adults with osteoporosis. Design Population based study involving emulation of a randomized target trial using electronic health ...
H. Lyu, S. Zhao, Licheng Zhang, Jie Wei, Xiao-xiao Li, Hui Li, Yi Liu, Pengbin Yin, V. Norvang, K. Yoshida, S. Tedeschi, C. Zeng, Guanghua Lei, P. Tang, D. H. Solomon   +14 more
semanticscholar   +1 more source

Long-Term Effect of Denosumab on Bone Disease in Patients with CKD

American Society of Nephrology. Clinical Journal, 2023
Visual Abstract Background The effect of long-term denosumab therapy and of denosumab discontinuation on the cortical bone of the hip regions in dialysis patients has not been studied.
Ken Iseri, Masahide Mizobuchi, R. Winzenrieth, L. Humbert, T. Saitou, Tadashi Kato, Yutaka Nakajima, Mikio Wakasa, K. Shishido, H. Honda   +9 more
semanticscholar   +1 more source

Risk comparison of osteonecrosis of the jaw in osteoporotic patients treated with bisphosphonates vs. denosumab: a multi-institutional retrospective cohort study in Taiwan

Osteoporosis International, 2023
In this multi-institutional retrospective cohort study, we compared the long-term risk of osteonecrosis of the jaw following the use of denosumab vs. bisphosphonates in osteoporotic patients.
Fang-Chun Liu, K. Luk, Yung-Chih Chen
semanticscholar   +1 more source

Pre-operative denosumab is associated with higher risk of local recurrence in giant cell tumor of bone: a systematic review and meta-analysis

BMC Musculoskeletal Disorders, 2020
Background In 2013, denosumab was introduced as peri-operative adjuvant treatment for giant cell tumor (GCT) of bone as it inhibits osteoclast activity.
Xi Chen, Hairui Li, Shibai Zhu, Yiou Wang, Wenwei Qian   +4 more
doaj   +1 more source

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment

Frontiers in Endocrinology, 2021
ObjectivesIn our previous 24-month study, we observed that teriparatide had some advantages over denosumab for bone mineral density (BMD) in glucocorticoid-induced osteoporosis (GIO) patients with prior bisphosphonate treatment.
Yasuaki Hirooka, Yasuaki Hirooka, Yuji Nozaki, Saki Okuda, Masafumi Sugiyama, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura   +7 more
doaj   +1 more source

Hypocalcemia Risk of Denosumab Across the Spectrum of Kidney Disease: A Population‐Based Cohort Study

Journal of Bone and Mineral Research, 2023
Denosumab can be used in patients with chronic kidney disease (CKD) but has been linked with cases of severe hypocalcemia. The incidence of and risk factors for hypocalcemia after denosumab use are not well established. Using linked health care databases
A. Cowan, N. Jeyakumar, E. McArthur, J. Fleet, T. Kanagalingam, I. Karp, Tayyab S. Khan, F. Muanda, D. Nash, S. Silver, J. Thain, M. Weir, A. Garg, K. Clemens   +13 more
semanticscholar   +1 more source

Adjuvant pharmacological strategies for the musculoskeletal system during long‐term space missions

British Journal of Clinical Pharmacology, EarlyView., 2023
Abstract Despite 2 h of daily exercise training, muscle wasting and bone loss are still present after 6‐month missions to the international space station. Some crew members lose bone much faster than others. In preparation for missions to the Moon and Mars, space agencies are therefore reviewing their countermeasure portfolios.
Friederike Thomasius, Dominik Pesta, Jörn Rittweger   +2 more
wiley   +1 more source